The FDA on May 27, 2026, approved DECNUPAZ®, a CD123-directed antibody and alkylating agent conjugate, for adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). DECNUPAZ® is a product of AbbVie, Inc.
Bottom Ad
Advertisement
Subscribe
Top Ad
Advertisement